about
Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality.Deleterious impact of feto-maternal MHC compatibility on the success of pregnancy in a macaque model.The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization.Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation.Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients.Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype.Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection.[Kidney nephrectomy after allograft failure]Immunoglobulin IgA, IgD, IgG, IgM and IgG subclass reference values in adultsMaintaining immunosuppressive treatment after early allograft nephrectomy does not reduce the risk of anti-HLA allosensitizationInterference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch resultsPregnancy after kidney transplantation: outcome and anti-human leucocyte antigen alloimmunization risk
P50
Q36918427-EA07D7AA-F244-4E71-8695-F7365E9A9747Q38174479-1D5ADFF3-F904-45FA-9C8B-93059C56EF2BQ39558945-20C53276-A1F2-4ED5-8C16-FE91F21C73C5Q40046767-C9AD86FD-B0E7-49F0-8352-60DC0683C076Q40907143-5B8353DD-B16B-4B4C-9CD7-F049DE01C043Q43297660-AA0118DC-777F-4B55-B0C2-A7AE10BB05D2Q44127877-3B0FD26C-3960-49D2-8784-4664079EF973Q44604343-B6E91147-8D9E-4339-A2DA-F6DB9F33D157Q46748325-F49CCC2B-D788-4E23-86A9-B6BA1022F523Q51755061-98A6F0F1-7789-46FF-B261-FEC1D784AAEDQ86120859-9DE00107-FE60-45C4-BCAD-3ACE508E7E08Q86835020-AF1A0B91-F986-41E4-A0E0-EF21A3747F83Q87099272-1F45748E-A71C-4E51-878D-3BBFA547D595Q87233834-191716CC-6C52-456B-9F4B-1EE0D84647DFQ88048598-8CC38D88-4D3B-4CF8-B914-3B67D8D46FDE
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2441-6145
@en
name
Nicolas Congy-Jolivet
@ast
Nicolas Congy-Jolivet
@en
Nicolas Congy-Jolivet
@es
Nicolas Congy-Jolivet
@nl
type
label
Nicolas Congy-Jolivet
@ast
Nicolas Congy-Jolivet
@en
Nicolas Congy-Jolivet
@es
Nicolas Congy-Jolivet
@nl
prefLabel
Nicolas Congy-Jolivet
@ast
Nicolas Congy-Jolivet
@en
Nicolas Congy-Jolivet
@es
Nicolas Congy-Jolivet
@nl
P106
P21
P31
P496
0000-0002-2441-6145